INTRODUCTION
============

Recently, as comparative-effectiveness research (CER) and health-technology assessment (HTA) are being widely implemented, the need for systematic reviews (SR) with meta-analysis is growing \[[@b1-epih-36-e2014016]-[@b3-epih-36-e2014016]\]. In particular, SR methodology for randomized controlled clinical trials (RCT), which compare effectiveness of drug or procedural interventions, has been established on the Cochrane Handbook for Systematic Reviews of Interventions by Higgins et al. \[[@b4-epih-36-e2014016]\].

However, CER and HTA involve analyses of diagnostic tests accuracy as well as that of interventional trials. In reality, modern medicine includes a majority of diagnostics: one can only administer right treatment and obtain positive results---in regards to survival rates, for instance---with the help of accurate diagnosis. Accordingly, SR methodology regarding diagnostic test assessments (DTA) is clearly required. However, SR methodology of DTA is currently in development, as indicated on the Cochran Collaboration website \[[@b5-epih-36-e2014016],[@b6-epih-36-e2014016]\]. At such a point, this article will overview DTA-related concepts and issues of SR methodology proposed by the Cochran Collaboration.

STEPS OF SYSTEMATIC REVIEWS
===========================

[Table 1](#t1-epih-36-e2014016){ref-type="table"} shows a comparison of the concepts and indicators detailing each procedural step in conducting SR for effectiveness of interventional trials and accuracy of diagnostic tests. Based on this table, the following content may be proposed.

Making the answerable questions
-------------------------------

The first step in a SR is to convert facing problems into some answerable questions. The patient or population, intervention, comparator, outcomes (PICO) method is being postulated as a viable tool for this process in SR of interventional trials \[[@b7-epih-36-e2014016]\].

The SR of DTA, however, begin with addressing the 8 aspects of 'PPP-ICP-TR' \[[@b6-epih-36-e2014016]\]. The first 'P' refers to patient characteristics, thus coinciding with the 'P' of the PICO, but the second and third 'P' refer to presentation, which concerns a patient's major symptoms, as well as prior tests, which are used for patient diagnosis. The 'I' refers to index tests, which will be used in conducting systematic reviews, while the 'C' refers to comparator tests, which are regular procedures comparative to the index test. Accordingly, the 'IC' for DTA may correspond to the 'IC' for interventional trials. The last 'P' stands for 'purpose', which may be divided largely into 3 parts: 1) changing the conventional comparator test into the index test (replacement), 2) conducting comparator tests on those who tested positively in index tests, as to obtain a more accurate diagnosis (triage), and 3) conducting index tests on those who tested negatively in comparator tests, as to reduce false-negative results (add-on). The 'T' stands for the 'target disorder' of any given SR and corresponds with the 'O' of the PICO method. The final 'R' refers to the 'reference standard', or, more specifically, the gold standard.

Indeed, a highly diverse range of information must be examined in order to conduct SR of DTA. Notably, addressing the 4 categories of test--namely, the prior test, index test, comparator test, and reference standard--requires that the concepts be clearly differentiated according to context. For instance, when conducting SR for choice between breast ultrasonography and breast magnetic resonance imaging (MRI) as additional examinations for diagnosis of breast cancer on women who showed dense mammography, the index test, comparator test, prior test, and reference standard would belong to breast MRI, breast ultrasonography, mammography, and pathologic results of breast tissues, respectively.

Searching literature
--------------------

While key words for performing SR of interventional trials might include 'intervention' (the 'I' of the 'PICO' method), while those for diagnostic studies might include 'index test' (the 'I' of 'PPP-ICP-TR') and the target disorder (the 'T' of 'PPP-ICP-TR'). Moreover, in interventional trials, filtering study design for RCT while focusing on the topics concerning the intervention can be an effective search strategy, as most interventional trials use the RCT design. However, as diagnostic tests utilize a diverse range of research design, such as cross-sectional studies (and not just comparative RCTs), it is meaningless to filter for research designs when searching for literature concerning diagnostic tests.

Evaluating individual article and extracting information
--------------------------------------------------------

As for tools that evaluate the quality of each article, risk of bias (ROB) if applicable, as proposed by Higgins et al. \[[@b8-epih-36-e2014016]\], as well as Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) \[[@b9-epih-36-e2014016]\], have been developed for interventional trials and diagnostic tests, respectively. QUADAS-2 is the revised, 2011 version of the 2003 QUADAS and consists of 4 dimensions -- patient selection, index test, reference standard, and finally, flow and timing, the first 3 of which requires an answer among the 3 available responses (yes/high, no/low, and unclear) \[[@b10-epih-36-e2014016]\]. An accessible Korean adaptation of the QUADAS-2 would be both, convenient and highly beneficial.

As for data extraction in SR of interventional trials, response rates (%) among the treatment and control groups should be obtained from the articles chosen for review. With respect to diagnostic tests, however, sensitivity and specificity of the tests are essential \[[@b11-epih-36-e2014016]\]. Diagnostic tests also provide predictive values, but these change according to disease prevalence and thus, are not appropriate for use in SR of DTA \[[@b12-epih-36-e2014016]\]. Likewise, sensitivity and specificity have been used, precisely as they are not associated with disease prevalence \[[@b13-epih-36-e2014016]\]. However, these factors also change according to threshold level and therefore, receiver operator characteristic (ROC) curves should necessarily accompany their use \[[@b14-epih-36-e2014016]\].

When calculating relevant indices in order to detect new information in the extracted data, the number needed to treat in interventional trials should be calculated from the reciprocal values corresponding to the difference in the response rates of the treatment and control groups \[[@b15-epih-36-e2014016]\]. In contrast, SR of DTA could rather calculate a diagnostic odds ratio (DOR) by dividing the product of sensitivity and specificity (true results) by the product of the values that count as false results \[[@b16-epih-36-e2014016],[@b17-epih-36-e2014016]\]. This value is referred to as an OR, as it is in the same form as ad/bc in a 2×2 table: the larger the value, the higher will sensitivity and specificity be in relation to each another. In other words, the larger the value, the closer one will approach the left upper maximum of the ROC curve and consequently, the larger the area under the curve will be \[[@b14-epih-36-e2014016]\].

In order to clearly display the extracted data, SR of interventional trials employ forest plots \[[@b18-epih-36-e2014016]\]. However, SR of DTA use coupled forest plots to show information concerning both sensitivity and specificity \[[@b19-epih-36-e2014016]\]. In addition, because sensitivity and specificity singularly change according to threshold level, summary ROC (SROC) curves accompany the plots \[[@b20-epih-36-e2014016]\]. The size of the mark may be changed according to the sample size of articles selected or standard error.

Meta-analysis
-------------

In order to conduct a meta-analysis, heterogeneity among the selected articles must be examined. Currently, SR of interventional trials assess heterogeneity using I^2^ values \[[@b21-epih-36-e2014016]\]. Summary statistics may be calculated according to fixed-effect models, if homogeneity is confirmed, or according to random-effect models, if heterogeneity is confirmed.

However, taking the trade-offs concerning sensitivity and specificity into the account, SR of DTA assume heterogeneity, except in special cases. In particular, when thresholds, such as standards in hypertension diagnoses, continuously change over time, a subgroup analysis must be conducted according to the covariate that reflects this change \[[@b10-epih-36-e2014016]\]. Thus there are no statistical methods designated to assess heterogeneity in SR of DTA, and additional analyses involving hierarchical random-effect models are required mostly. Currently, the two methods such as bivariate method and Rutter & Gatsonis HSROC method have been developed for this purpose. They use different statistical values for calculation \[[@b6-epih-36-e2014016]\]. The bivariate method uses sensitivity and specificity, while the HSROC method uses thresholds and DOR \[[@b20-epih-36-e2014016]\]. Though, RevMan 5.3 supports neither method of analysis directly, when the statistical estimates from SAS PROC NLMIXED (SAS Inc., Cary, NC, USA) or STATA METANDI (StataCorp, College Station, TX, USA) are additionally entered, RevMan can calculate summary statistics \[[@b21-epih-36-e2014016]\]. If fewer studies and fixed threshold were used, the Moses-Littenberg SROC might be useful as well, for summary statistics.

Reporting
---------

Reporting results of interventional trials and diagnostic tests may follow the guidelines postulated by Consolidated Standards of Reporting Trials (CONSORT) \[[@b23-epih-36-e2014016]\] and Standards for Reporting of Diagnostic Accuracy (STARD) guidelines \[[@b24-epih-36-e2014016]\], respectively. Additionally, while Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) is a guideline for reporting results of SR of interventional trials \[[@b25-epih-36-e2014016]\], there is yet none available for that of DTA. Moreover, while funnel plots may be used to indirectly check for publication bias in SR of interventional trials, there is no tool currently available for such evaluations in SR of DTA.

CONCLUSIONS AND SUGGESTIONS
===========================

The fact that methodology regarding SR of DTA is still in development implies that several issues remain unaddressed. Experts are yet to reach a consensus and the complex nature of DTA increase the quantum of issues than those in the case of interventional trials \[[@b26-epih-36-e2014016]\]. Furthermore, the content discussed in the present study opens for changes at any time. Nevertheless, I deliberated on the methodology for SR of DTA so as to encourage Korean researchers to take interest and actively participate in the process of refining this methodology. Finally, we hope that epidemiologists and biostatisticians will attempt several SR in near future.
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###### 

Comparison of issues related to systematic reviews (SR) of intervention trials and diagnostic tests

  Step                           Issues                          SR of intervention trials    SR of diagnostic tests
  ------------------------------ ------------------------------- ---------------------------- ------------------------------
  Ask                            Making questions                PICO                         PPP-ICP-TR
  Acquire                        Main keyword                    Intervention                 Index test & target disorder
  Searching                      Filtering                       No filtering                 
  Assess                         Quality level                   ROB                          QUADAS-2
  Extracting results             Proportion of response (%)      Sensitivity & Specificity    
  New index                      NNT                             DOR                          
  Summary figures                Forest plot                     Coupled Forest Plot & SROC   
  Analysis                       Heterogeneity index             I^2^                         (SROCs by prediction region)
  On homogeneous                 Fixed effect model              (Moses-Littenberg SROC)      
  On heterogeneous               Random effect model             hierarchical models          
  Report                         Standard for original article   CONSORT                      STARD
  Standard for summary results   PRISMA                          Not available                
  Publication bias               Funnel plot                     Not available                

ROB, risk of bias; QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2; NNT, number needed to treatment; DOR, diagnostic odds ratio; SROC, summary receiver operator characteristic curve; CONSORT, Consolidated Standards of Reporting Trials; STARD, Standards for Reporting of Diagnostic Accuracy; PRISMA, Preferred Reporting Items for Systematic reviews and Meta-analysis.
